智通财经网·2025-08-28 06:57Core Viewpoint - The report from Credit Lyonnais indicates that Fosun Pharma (02196) demonstrated resilience in its Q2 performance, with a quarterly revenue increase of 7.2% and a net profit increase of 22.5%, primarily driven by strong sales of innovative products [1] Group 1: Financial Performance - Revenue increased by 7.2% quarter-on-quarter [1] - Net profit increased by 22.5% quarter-on-quarter [1] Group 2: Growth Drivers - Strong performance attributed to the sales of innovative products [1] - The new Employee Stock Ownership Plan (ESOP) is expected to enhance growth visibility and alleviate market concerns following leadership changes [1] Group 3: Forecast and Valuation - Core profit forecasts for Fosun Pharma have been raised by approximately 13% to 21% for the years 2023 to 2027 [1] - The target price for H-shares has been increased from HKD 15.6 to HKD 29.6, maintaining an outperform rating [1] Group 4: Strategic Initiatives - The ESOP plan for senior management is linked to achieving a 20% compound annual growth rate for both innovative drug sales and net profit from 2023 to 2027 [1] - Successful completion of licensing agreements for two self-developed molecules [1]